Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib: an international, multicentre, prospective, randomised, placebo-controlled phase 3 trial (GRID)

BACKGROUND: To date, only two agents, imatinib and sunitinib, have shown clinical benefit in patients with gastrointestinal stromal tumours (GISTs), but almost all metastatic GISTs eventually develop resistance to these agents, resulting in fatal disease progression. This phase 3 trial assessed effi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Demetri, George D, Reichardt, Peter, Kang, Yoon-Koo, Blay, Jean-Yves, Rutkowski, Piotr, Gelderblom, Hans, Hohenberger, Peter, Leahy, Michael, von Mehren, Margaret, Joensuu, Heikki, Badalamenti, Giuseppe, Blackstein, Martin, Cesne, Axel Le, Schöffski, Patrick, Maki, Robert G, Bauer, Sebastian, Nguyen, Binh Bui, Xu, Jianming, Nishida, Toshirou, Chung, John, Kappeler, Christian, Kuss, Iris, Laurent, Dirk, Casali, Paolo
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3819942/
https://ncbi.nlm.nih.gov/pubmed/23177515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(12)61857-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados